24/7 Market News Snapshot 13 January, 2025 – Delcath Systems Inc (NASDAQ:DCTH)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:DCTH) are discussed in this article.
Delcath Systems, Inc. has recently witnessed fluctuations in its stock market performance, opening at $12.98 and currently trading at $12.81, which marks a decline of approximately 11.59%. Following a previous session close at $11.48, this drop demonstrates a reversal after a notable upward trend. With a robust trading volume of 655.39K, there is evident market engagement, indicating increased interest or volatility surrounding the company. Analysts are advised to monitor significant resistance levels around $13 and potential support at the earlier closing price of $11.48 for insights into future price movements.

On a more positive note, Delcath has released encouraging preliminary financial results for the fourth quarter and the entire fiscal year ending December 31, 2024. The company anticipates total revenues of approximately $15.1 million for the fourth quarter and $37.2 million for the year. A significant contributor to these results is the HEPZATO KIT™, expected to generate around $13.7 million in the fourth quarter and $32.3 million for the full year. Concurrently, the CHEMOSAT® product line is projected to add roughly $1.4 million in the fourth quarter and $4.9 million for the year, reflecting sustained demand for Delcath’s innovative therapies.

Additionally, the company has achieved impressive gross margins between 80% and 85%, highlighting the effectiveness of its operational strategy. Delcath’s financial health is further supported by approximately $53.2 million in cash and short-term investments, alongside zero debt, thereby positioning the firm favorably for future opportunities. With a focus on enhancing patient outcomes through its proprietary treatments, particularly the FDA-approved HEPZATO KIT for metastatic uveal melanoma, Delcath Systems continues to solidify its role in advancing interventional oncology. An in-depth financial update and business outlook will be shared during the upcoming investor call slated for March 6, 2025.

Related news for (DCTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.